Cargando…

Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice

OBJECTIVE: Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby...

Descripción completa

Detalles Bibliográficos
Autores principales: Aitken, Jacqueline F., Loomes, Kerry M., Scott, David W., Reddy, Shivanand, Phillips, Anthony R.J., Prijic, Gordana, Fernando, Chathurini, Zhang, Shaoping, Broadhurst, Ric, L'Huillier, Phil, Cooper, Garth J.S.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797917/
https://www.ncbi.nlm.nih.gov/pubmed/19794060
http://dx.doi.org/10.2337/db09-0548
_version_ 1782175687121043456
author Aitken, Jacqueline F.
Loomes, Kerry M.
Scott, David W.
Reddy, Shivanand
Phillips, Anthony R.J.
Prijic, Gordana
Fernando, Chathurini
Zhang, Shaoping
Broadhurst, Ric
L'Huillier, Phil
Cooper, Garth J.S.
author_facet Aitken, Jacqueline F.
Loomes, Kerry M.
Scott, David W.
Reddy, Shivanand
Phillips, Anthony R.J.
Prijic, Gordana
Fernando, Chathurini
Zhang, Shaoping
Broadhurst, Ric
L'Huillier, Phil
Cooper, Garth J.S.
author_sort Aitken, Jacqueline F.
collection PubMed
description OBJECTIVE: Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby hA/hIAPP causes diabetes in hemizygous hA/hIAPP-transgenic mice. RESEARCH DESIGN AND METHODS: We chronically treated hemizygous hA/hIAPP transgenic mice with oral tetracycline to determine its effects on rates of diabetes initiation, progression, and survival. RESULTS: Homozygous mice developed severe spontaneous diabetes due to islet β-cell loss. Hemizygous transgenic animals also developed spontaneous diabetes, although severity was less and progression rates slower. Pathogenesis was characterized by initial islet β-cell dysfunction followed by progressive β-cell loss. Islet amyloid was absent from hemizygous animals with early-onset diabetes and correlated positively with longevity. Some long-lived nondiabetic hemizygous animals also had large islet-amyloid areas, showing that amyloid itself was not intrinsically cytotoxic. Administration of tetracycline dose-dependently ameliorated hyperglycemia and polydipsia, delayed rates of diabetes initiation and progression, and increased longevity compared with water-treated controls. CONCLUSIONS: This is the first report to show that treating hA/hIAPP transgenic mice with a modifier of hA/hIAPP misfolding can ameliorate their diabetic phenotype. Fibrillar amyloid was neither necessary nor sufficient to cause diabetes and indeed was positively correlated with longevity therein, whereas early- to mid-stage diabetes was associated with islet β-cell dysfunction followed by β-cell loss. Interventions capable of suppressing misfolding in soluble hA/hIAPP oligomers rather than mature fibrils may have potential for treating or preventing type 2 diabetes.
format Text
id pubmed-2797917
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-27979172011-01-01 Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice Aitken, Jacqueline F. Loomes, Kerry M. Scott, David W. Reddy, Shivanand Phillips, Anthony R.J. Prijic, Gordana Fernando, Chathurini Zhang, Shaoping Broadhurst, Ric L'Huillier, Phil Cooper, Garth J.S. Diabetes Original Article OBJECTIVE: Aggregation of human amylin/islet amyloid polypeptide (hA/hIAPP) into small soluble β-sheet–containing oligomers is linked to islet β-cell degeneration and the pathogenesis of type 2 diabetes. Here, we used tetracycline, which modifies hA/hIAPP oligomerization, to probe mechanisms whereby hA/hIAPP causes diabetes in hemizygous hA/hIAPP-transgenic mice. RESEARCH DESIGN AND METHODS: We chronically treated hemizygous hA/hIAPP transgenic mice with oral tetracycline to determine its effects on rates of diabetes initiation, progression, and survival. RESULTS: Homozygous mice developed severe spontaneous diabetes due to islet β-cell loss. Hemizygous transgenic animals also developed spontaneous diabetes, although severity was less and progression rates slower. Pathogenesis was characterized by initial islet β-cell dysfunction followed by progressive β-cell loss. Islet amyloid was absent from hemizygous animals with early-onset diabetes and correlated positively with longevity. Some long-lived nondiabetic hemizygous animals also had large islet-amyloid areas, showing that amyloid itself was not intrinsically cytotoxic. Administration of tetracycline dose-dependently ameliorated hyperglycemia and polydipsia, delayed rates of diabetes initiation and progression, and increased longevity compared with water-treated controls. CONCLUSIONS: This is the first report to show that treating hA/hIAPP transgenic mice with a modifier of hA/hIAPP misfolding can ameliorate their diabetic phenotype. Fibrillar amyloid was neither necessary nor sufficient to cause diabetes and indeed was positively correlated with longevity therein, whereas early- to mid-stage diabetes was associated with islet β-cell dysfunction followed by β-cell loss. Interventions capable of suppressing misfolding in soluble hA/hIAPP oligomers rather than mature fibrils may have potential for treating or preventing type 2 diabetes. American Diabetes Association 2010-01 2009-09-30 /pmc/articles/PMC2797917/ /pubmed/19794060 http://dx.doi.org/10.2337/db09-0548 Text en © 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Article
Aitken, Jacqueline F.
Loomes, Kerry M.
Scott, David W.
Reddy, Shivanand
Phillips, Anthony R.J.
Prijic, Gordana
Fernando, Chathurini
Zhang, Shaoping
Broadhurst, Ric
L'Huillier, Phil
Cooper, Garth J.S.
Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
title Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
title_full Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
title_fullStr Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
title_full_unstemmed Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
title_short Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
title_sort tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797917/
https://www.ncbi.nlm.nih.gov/pubmed/19794060
http://dx.doi.org/10.2337/db09-0548
work_keys_str_mv AT aitkenjacquelinef tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT loomeskerrym tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT scottdavidw tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT reddyshivanand tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT phillipsanthonyrj tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT prijicgordana tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT fernandochathurini tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT zhangshaoping tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT broadhurstric tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT lhuillierphil tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice
AT coopergarthjs tetracyclinetreatmentretardstheonsetandslowstheprogressionofdiabetesinhumanamylinisletamyloidpolypeptidetransgenicmice